Clinical Trials for Ovarian Cancer

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: Adults with suspected or confirmed stage IIIC–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive laparotomy (BLOODS ≥2, Hgb ≥10 g/dL) are randomized to intraoperative acute normovolemic hemodilution (autologous whole-blood collection with crystalloid/colloid replacement and reinfusion) versus standard intraoperative care. The trial tests whether ANH reduces perioperative allogeneic red blood cell transfusion within 30 days.

ClinicalTrials.gov ID: NCT06290193

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent, platinum-refractory or -resistant epithelial ovarian cancer (including carcinosarcoma), ECOG 0–2, receive autologous B7‑H3 (CD276)–targeted CAR T cells after lymphodepletion, administered either intraperitoneally for peritoneal-only disease or intravenously if extra-peritoneal or IP not feasible. Investigational therapy targets broadly overexpressed B7‑H3; trial assesses feasibility/safety with dose escalation and early response signals.

ClinicalTrials.gov ID: NCT06646627

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Enrolling adults with measurable high-grade serous ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior lines (platinum-sensitive and -resistant cohorts; ECOG 0–1), excluding significant ILD/pneumonitis and other key comorbidities. Investigational CDH6-targeting antibody-drug conjugate raludotatug deruxtecan (anti-CDH6–DXd topoisomerase I payload) is combined with either carboplatin, paclitaxel, or bevacizumab, with chemotherapy for up to six cycles and continued R-DXd until progression.

ClinicalTrials.gov ID: NCT06843447

Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–2) receive oral CPI-0209 (tulmimetostat), a dual EZH2/EZH1 inhibitor aiming to reverse epigenetic platinum resistance, combined with carboplatin followed by CPI-0209 maintenance. Prior bevacizumab or PARP inhibitor is allowed; excludes platinum-resistant disease and significant comorbidities.

ClinicalTrials.gov ID: NCT05942300

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with newly diagnosed FIGO III–IV high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma planned for neoadjuvant chemotherapy are randomized to standard carboplatin/paclitaxel plus bevacizumab with surgery and maintenance versus the same regimen plus intraperitoneal IMNN-001 (GEN-1), a DNA–lipopolymer IL‑12 immunotherapy that enhances local T/NK-cell activity, given weekly through adjuvant therapy and continued with bevacizumab in HRP/BRCA– patients. Trial assesses histologic minimal residual disease at second-look laparoscopy, with PFS and OS as secondary endpoints.

ClinicalTrials.gov ID: NCT05739981

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with advanced solid tumors—emphasizing platinum‑refractory/resistant ovarian cancer—who have exhausted standard therapy receive CUSP06 (AMT‑707), a cadherin‑6–targeted IgG1 antibody‑drug conjugate delivering an exatecan (topoisomerase‑I) payload, given IV every 21 days. Open‑label dose escalation with tumor‑specific expansions; key exclusions include prior topoisomerase‑I ADCs and active CNS disease.

ClinicalTrials.gov ID: NCT06234423

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1) are randomized to SON-1010 (IL-12 fused to an albumin-binding fragment to prolong half-life and localize to tumors, enhancing IFN-γ–mediated antitumor immunity) alone, SON-1010 plus atezolizumab (PD-L1 inhibitor), or standard of care; early parts include dose escalation of the combination. Key exclusions include active autoimmune disease requiring treatment, uncontrolled infections, active CNS metastases, and recent checkpoint inhibitor use.

ClinicalTrials.gov ID: NCT05756907

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (relapse ≤6 months after last platinum; ≤2 prior cytotoxic lines) receive carboplatin/paclitaxel plus oral defactinib, a reversible ATP-competitive FAK/Pyk2 inhibitor aimed at re-sensitizing to platinum. Primary aims are safety/tolerability and objective response by RECIST 1.1.

ClinicalTrials.gov ID: NCT03287271

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets adult patients with advanced solid malignancies and evaluates the safety and efficacy of CRX100, an investigational immunotherapy combining autologous T cells and oncolytic vaccinia virus, as monotherapy and in combination with Pembrolizumab.

ClinicalTrials.gov ID: NCT04282044

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial enrolls adults with measurable ovarian, endometrial, triple-negative breast, or non-small cell lung cancers to evaluate the safety and efficacy of Farletuzumab Ecteribulin (MORAb-202), an antibody-drug conjugate targeting folate receptor alpha, which delivers eribulin to cancer cells.

ClinicalTrials.gov ID: NCT04300556